Medivir's experimental hep C treatment TMC435 cured as many as 80% of patients 24 weeks after treatment ended. The mid-stage Aspire trial looked at the medicine in combination with the current standard of care of interferon and ribavirin. The results were announced today at a medical meeting in Barcelona. About 51% of patients who didn't respond to prior treatment were cured after taking TMC435 with interferon and ribavirin, compared with 19% who didn't have TMC435 in the treatment regimen.
TMC435治愈80%